Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics,...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving...